Abstract:e24276 Background: Hepatocellular carcinoma (HCC), the most common hepatic malignancy, is the second leading cause of cancer-related death worldwide. China accounts for more than 50% of new HCC cases and deaths in the world. The genomic profiles of HCC in Chinese patients had not been thoroughly elucidated to facilitate diagnosis and treatment. Methods: FFPE tumor and matched blood samples of 181 Chinese HCC patients, including 152 males (median age of 54) and 29 females (median age of 52), were collected for next-generation sequencing-based 450 genes panel assay. Genomic alterations (including single base substitutions, short and long insertions/deletions, copy number variations, and gene rearrangement in selected genes) and tumor mutational burden were assessed. In addition, the expression of tumor cell PDL1 was also evaluated by FDA-cleared DAKO 22c3 antibody. Results: The most frequently mutated genes in 181 Chinese HCC were TP53 (59.7%), TERT (34.3%), CTNNB1 (21.5%), AXIN1 (12.2%), RB1 (11.0%), STK24 (11.0%), ARID1A (9.9%), CCND1 (7.7%), TSC2 (6.6%) and FGF19 (6.6%). The mutation rates of TERT (p = 0.027) and RB1 (p = 0.016) were significantly higher in patients (pts) with TMB greater than the cohort medium of 7.2 muts/Mb. In addition, loss of function mutation of PBRM1 was found in 2.8% of the pts. About 7% of the patients had TMB value higher than 20 muts/Mb, compared to 1-2% in Western HCC pts, and 31% higher than 10 muts/Mb. Seventy-four patients (median age 54 years; median TMB 6.8 muts/Mb) had tumorous PDL1 expressions assessed by IHC assay. Thirty-six percent of patients were positive of PDL1 (tumor portion score TPS greater than 1%). Only three pts possessed both high TMB and high PDL1 expression (TPS > 50). No correlation was observed between the expression of PDL1 and TMB (r = 0.1). Conclusions: This is the first genomic profiling study of Chinese HCC pts along with TMB and PDL1 expression results. With less actionable gene alterations but more often high TMB and PDL1 expression than their Western counterparts, Chinese HCC pts could potentially benefit more from immune check point inhibitor-based therapies. However, no correlation was observed between the expressions of PDL1 and TMB values.

Alterations of Cdkn2(P16/Mts1) Exon 2 in Human Hepatocellular Carcinoma

Mutation Analysis of Novel Human Liver-Related Putative Tumor Suppressor Gene in Hepatocellular Carcinoma

Infrequent Mutations and No Methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/mts2) in Hepatocellular Carcinoma in Taiwan.

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

[Study of Deletion and Mutation of P16 Gene in Primary Hepatocellular Carcinoma].

Polymorphism of P16ink4a Gene and Rare Mutation of P15ink4b Gene Exon2 in Primary Hepatocarcinoma

[P16 and Cyclind1 Protein Expression and P16 Gene Mutation in Primary Human Hepatocellular Carcinoma].

[A Study on the Inactivation of P16 Genes and the Expression of P16 Protein in Primary Hepatocellular Carcinomas].

[Correlation of C-Myc Gene Amplification, MTS1/p16 Gene Alternation, and HBV Infection in Human Hepatocellular Carcinoma].

Analysis on point mutation of the CDKN2/p16 gene in lung cancer

The Genetic Alteration of P16 and CDK4 Genes and Their Relations to HBV Infection in Human Hepatocellular Carcinoma

Association of Low P16ink4a and P15ink4b Mrnas Expression with Their Cpg Islands Methylation with Human Hepatocellular Carcinogenesis

Characterization of a base-resolution common deletion region within CDKN2A gene in cancers and its biological and clinical significances

Genetic Aberration in Primary Hepatocellular Carcinoma: Correlation Between P53 Gene Mutation and Loss-of-hetero- Zygosity on Chromosome 16Q21-Q23 and 9P21-P23

Loss of Heterozygosity on Chromosome 10Q22-10Q23 and 22q 11.2- 22q 12.1 and P53 Gene in Primary Hepatocellular Carcinoma

[Mutation Analysis of P16 Gene in Non-Small Cell Lung Carcinomas].

The Status of P16 Gene in Primary Hepatocellular Carcinoma from a Chinese Population

Allelic Loss And Gain, But Not Genomic Instability, As The Major Somatic Mutation In Primary Hepatocellular Carcinoma

Mutation research of c-myc gene in hepatocellular carcinoma

Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation

Study of CDKN2/p16 Gene Existence State in Lung Cancer